News

The National Institute for Health and Care Excellence10h
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...
Relay Therapeutics: Trying To Find That Right Price
Relay Therapeutics gains capital via licensing, reduces costs, and advances its promising PI3K-alpha inhibitor. See why RLAY ...